Define Ventures Appoints Carolyn Magill as Venture Partner
SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.
Carolyn is a seasoned healthcare executive and two-time CEO, having held executive leadership positions across multiple corners of the ecosystem. Prior to joining Define, Carolyn was CEO of Aetion, whose platform transforms real-world data into regulatory-grade evidence for critical healthcare decisions. She also previously served as CEO of Remedy Partners, the premier bundled payments software and services company, and as Executive Vice President of Payer Strategy and Operations at Evolent Health, where she helped drive the company's progression from startup through IPO. She also held several leadership roles at UnitedHealth Group, including Chief Operating Officer of its Community and State plan in New Jersey.
"Carolyn's extensive experience across payer, provider, and pharmaceutical sectors makes her uniquely qualified to guide the next generation of health tech innovators," said Lynne Chou O'Keefe, founder and managing partner at Define Ventures. "Having had the privilege of partnering with Carolyn as an advisor for many years, we're confident her deep expertise, particularly in data and AI applications within the pharmaceutical landscape, will be invaluable to our partner companies."
"Define represents the best of venture — an incredible founder community and a team of experienced operators who truly understand what it takes to build in healthcare," said Magill. "Throughout my career, I've worked across many corners of healthcare, and joining Define allows me to bring that experience to the earliest stages of innovation, helping founders turn ideas into impact."
Carolyn's appointment complements Define Ventures' existing venture partners, Bruce Broussard, former CEO of Humana, and Frank Williams, co-founder and former CEO of Evolent Health, creating a powerful trio of industry leaders with comprehensive experience across payer, provider and pharmaceutical sectors. Together, they bring unparalleled strategic depth to Define's partner companies.
Define Ventures has $800 million in assets under management and partners with companies at the seed, series A and series B stages. The firm impacts leading health tech entrepreneurs with its high conviction approach, partnering with over two dozen companies including Hims & Hers (NYSE: HIMS), Unite Us and Cohere Health.To learn more about Define Ventures, visit www.definevc.com.
About Define Ventures
Define Ventures is one of the largest funds focused on early-stage health tech companies. With $800 million AUM, we take a high conviction approach in partnering with companies in the earliest stages. We believe the future of healthcare will be defined by those who bring together a deep understanding of the healthcare ecosystem paired with a technology-driven mindset. Our team was built to this vision, bringing together founders and investors who built category-defining companies and delivered over $25 billion in exit value, including Livongo (NYSE: LVGO), Evolent (NYSE: EVH), and Hims & Hers (NYSE: HIMS).
View original content to download multimedia:https://www.prnewswire.com/news-releases/define-ventures-appoints-carolyn-magill-as-venture-partner-302397696.html
SOURCE Define Ventures
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
6 minutes ago
- Business Upturn
BRBR LOSS ALERT: BellRing Brands, Inc. Investors with Losses are Reminded of the Ongoing Securities Fraud Investigation – Contact BFA Law (NYSE:BRBR)
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BellRing Brands, Inc. (NYSE: BRBR) for potential violations of the federal securities laws. If you invested in BellRing, you are encouraged to obtain additional information by visiting: Why is BellRing Being Investigated? BellRing Brands operates in the convenient nutrition category. The Company's primary brands include Premier Protein and Dymatize, which offer ready-to-drink ('RTD') protein shakes and powders. During the relevant period, the Company stated that Premier Protein 'hit an all-time high in household penetration' and that 'demand remains strong.' The Company also stated that its growth was 'strong in all channels,' driven by 'distribution expansion, accelerating velocities and incremental promotional activity.' In truth, the Company's sales growth during the relevant period may have been driven by temporary trade inventory loading at several key retailers, not sustainable end-consumer demand. The Stock Declines as the Truth Is Revealed On May 5, 2025, after market hours, BellRing revealed that starting in Q2 2023, 'several key retailers lowered their weeks of supply on hand,' which would create a headwind to Q3 2025 growth. The Company also announced it was expanding promotions to boost sales and 'offset [] third quarter reductions in retailer trade inventory levels.' On this news, the price of BellRing stock fell $13.96 per share, or more than 18%, from $77.34 per share on May 5, 2025, to $63.38 per share on May 6, 2025. Then, on August 4, 2025, after market hours, BellRing announced disappointing quarterly consumption of Premier Protein RTD Shakes, which had been expected to outpace shipments by a wider margin given previously announced retailer destocking, but instead came 'more in line' with shipments. On this news, the price of BellRing Brands stock fell $17.46 per share, or nearly 33%, from $53.64 per share on August 4, 2025, to $36.18 per share on August 5, 2025. Click here for more information: What Can You Do? If you invested in BellRing you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212.789.3619
Business Upturn
7 minutes ago
- Business Upturn
CNC LOSS ALERT: Centene Corporation Investors with Losses are Reminded of the September 8 Class Action Deadline – Contact BFA Law (NYSE:CNC)
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Centene Corporation (NYSE: CNC) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Centene, you are encouraged to obtain additional information by visiting: Investors have until September 8, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned: Lunstrum v. Centene Corporation, et al. , No. 25-cv-05659. Why was Centene Sued for Securities Fraud? Centene is a healthcare company that focuses on providing services to consumers enrolled in government-sponsored healthcare programs like Medicaid and Medicare, as well as those that purchase insurance under the Affordable Care Act from the Health Insurance Marketplace. On December 12, 2024, Centene announced financial guidance for fiscal year 2025 which the company said reflected '[s]tability in earnings power in the face of unprecedented headwinds.' Next, on February 4, 2025, Centene increased its 2025 guidance due to enrollment 'overperformance.' Then, on April 25, 2025, Centene again increased 2025 guidance due to continued strong growth in enrollment and retention, while touting the 'progress we are making as an organization while navigating a dynamic policy landscape.' In truth, the majority of the market that Centene serves was experiencing lower than expected enrollment growth and increased morbidity rates, or frequency of disease and illness. The Stock Declines as the Truth is Revealed On July 1, 2025, Centene abruptly withdrew its previous guidance after reviewing an independent actuarial report from Wakely Consulting Group which showed that overall market growth in 22 of the 29 states Centene serves was lower than expected and that morbidity in those states was significantly higher than expected. On this news, the price of Centene stock fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025. Click here for more information: What Can You Do? If you invested in Centene you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212.789.3619
Yahoo
30 minutes ago
- Yahoo
Investors Can Find Comfort In Covenant Logistics Group's (NYSE:CVLG) Earnings Quality
Explore Covenant Logistics Group's Fair Values from the Community and select yours Covenant Logistics Group, Inc.'s (NYSE:CVLG) stock was strong despite it releasing a soft earnings report last week. However, we think the company is showing some signs that things are more promising than they seem. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. How Do Unusual Items Influence Profit? Importantly, our data indicates that Covenant Logistics Group's profit was reduced by US$9.8m, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. If Covenant Logistics Group doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Our Take On Covenant Logistics Group's Profit Performance Because unusual items detracted from Covenant Logistics Group's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Based on this observation, we consider it likely that Covenant Logistics Group's statutory profit actually understates its earnings potential! Unfortunately, though, its earnings per share actually fell back over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. Every company has risks, and we've spotted 1 warning sign for Covenant Logistics Group you should know about. This note has only looked at a single factor that sheds light on the nature of Covenant Logistics Group's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
